Search Technologies

There is a marked increase in immunosuppressive myeloid progenitors and myeloid cells in tumors and at metastatic tissue sites, rendering these types of cells useful in cancer therapeutics – especially after genetic modifications to improve their anti-tumor properties. The National Cancer Institute (NCI) seeks research co-development or licensing for genetically engineered myeloid cells (GEMys) for use in cancer immunotherapy.

Scientists at the National Cancer Institute's Molecular Targets Laboratory have modified the Cnidarin-derived griffithsin compound to have greater storage time and stability. Griffithsin compounds are a class of highly potent proteins capable of blocking the HIV virus from penetrating T cells. The National Cancer Institute seeks parties interested in collaborative research to license or co-develop large-scale recombinant production of the compound.

Researchers at the National Cancer Institute (NCI) have isolated two high affinity anti-mesothelin single domain antibodies (also known as nanobodies), A101 and G8. These antibodies have been isolated from NCI’s newly developed camel single domain (VHH) libraries by phage display. The antibodies have a high affinity for mesothelin-positive tumor cells from both human and mouse origins. The NCI seeks licensing and/or co-development research collaborations to advance the development and commercialization of these antibodies.

Cancer therapies that specifically target Glypican 2 (GPC2) are strong therapeutic candidates for pediatric patients with neuroblastoma and other GPC2 expressing cancers. The inventors at the National Cancer Institute (NCI) have developed and isolated two new antibodies that target GPC2 (CT3 and CT5) that are available for licensing and co-development.

The National Cancer Institute Laboratory of Molecular Biology seeks parties to license or co-develop and commercialize antibody drug/toxin conjugates as liver cancer therapy and diagnostics.

The National Cancer Institute (NCI) seeks licensees for a method of high-throughput generation of induced pluripotent stem cells carrying antigen-specific T cell receptors from tumor infiltrated lymphocytes.

The National Cancer Institute seeks parties to co-develop soluble forms of CD4 as potent HIV-1 therapeutics.

The National Cancer Institute (NCI) seeks research and co-development partners and/or licensees for human monoclonal antibodies and antibody-based therapeutics targeting the B-cell antigen CD22

The National Cancer Institute's Cancer and Inflammation Program is seeking statements of capability or interest from parties interested in licensing monoclonal antibodies to IGF-1 and IGF-II for the treatment of cancer.